Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 shRNA-modified CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Tianjin First Central Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
PD-1 shRNA-modified CD19 CAR-T cells are an investigational autologous cell therapy developed for the treatment of relapsed or refractory B-cell lymphoma. This therapeutic approach involves the genetic modification of a patient's T cells to express a chimeric antigen receptor (CAR) specific for the CD19 antigen, a protein widely expressed on the surface of B-cell malignancies. To enhance the potency and durability of the CAR-T cells, they are further engineered with short hairpin RNA (shRNA) technology designed to knockdown the expression of the programmed cell death protein 1 (PD-1) receptor. By reducing PD-1 levels, these modified CAR-T cells are intended to be less susceptible to exhaustion induced by the PD-1/PD-L1 inhibitory pathway within the tumor microenvironment, potentially leading to improved clinical outcomes compared to conventional CAR-T therapies.
- Other names
- PD-1 expression reduced CD19 CAR-T cellsPD1 expression reduced CD19 CAR-T cellsPD 1 expression reduced CD19 CAR-T cellsPD-1 shRNA-CD19-CAR-TPD1 shRNA-CD19-CAR-TPD 1 shRNA-CD19-CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1 shRNA-modified CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 shRNA-modified CD19 CAR-T cells.